Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 2

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Fitness Trackers × Tumor-Agnostic × Clear all
NCT02779725 2023-11-08

SCH

University of Utah

Phase NA Completed
884 enrolled
Tumor-Agnostic

Neoplasms

NCT02659358 2017-09-25

Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer

Cedars-Sinai Medical Center

Completed
37 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡